Replies to post #18133 on Biotech Values

[DewDiligence]

>Because it's a crock maybe?<

Crock or not, Denosumab could become a $3B drug by the end of the decade if not sooner.

With the leading edge of the baby boom turning 60 next year, a convenient, safe, and efficacious drug for osteoporosis is going to have a heck of a tail wind.

It remains to be seen whether Denosumab will be all of these things, but the upside is colossal.